Suppr超能文献

肿瘤坏死因子相关凋亡诱导配体(TRAIL)受体在胰腺导管腺癌的恶性细胞和基质细胞中均有表达。

TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma.

作者信息

Dall'Ora Massimiliano, Rovesti Giulia, Reggiani Bonetti Luca, Casari Giulia, Banchelli Federico, Fabbiani Luca, Veronesi Elena, Petrachi Tiziana, Magistri Paolo, Di Benedetto Fabrizio, Spallanzani Andrea, Chiavelli Chiara, Spano Maria Carlotta, Maiorana Antonino, Dominici Massimo, Grisendi Giulia

机构信息

Rigenerand S.r.l. Medolla 41036, Italy.

Division of Oncology, Laboratory of Cellular Therapy, Department of Medical and Surgical Sciences of Children & Adults, University of Modena and Reggio Emilia Modena 41124, Italy.

出版信息

Am J Cancer Res. 2021 Sep 15;11(9):4500-4514. eCollection 2021.

Abstract

This study assesses the expression of all TNF-related apoptosis-inducing ligand (TRAIL) receptors in pancreatic ductal adenocarcinoma (PDAC) tumor tissue. We aimed to include TRAIL receptor expression as an inclusion parameter in a future clinical study using a TRAIL-based therapy approach for PDAC patients. Considering the emerging influence of PDAC desmoplastic stroma on the efficacy of anti-PDAC therapies, this analysis was extended to tumor stromal cells. Additionally, we performed PDAC stroma characterization. Our retrospective cohort study (N=50) included patients with histologically confirmed PDAC who underwent surgery. The expression of TRAIL receptors (DR4, DR5, DcR1, DcR2, and OPG) in tumor and stromal cells was evaluated by immunohistochemistry (IHC). The amount of tumor stroma was assessed by anti-vimentin IHC and Mallory's trichrome staining. The prognostic impact was determined by the univariate Cox proportional hazards regression model. An extensive expression of functional receptors DR4 and DR5 and a variable expression of decoy receptors were detected in PDAC tumor and stromal cells. Functional receptors were detected also in metastatic tumor and stromal cells. A poor prognosis was associated with low or absent expression of decoy receptors in tumor cells of primary PDAC. After assessing that almost 80% of tumor mass was composed of stroma, we correlated a cellular-dense stroma in primary PDAC with reduced relapse-free survival. We demonstrated that TRAIL functional receptors are widely expressed in PDAC, representing a promising target for TRAIL-based therapies. Further, we demonstrated that a low expression of DcR1 and the absence of OPG in tumor cells, as well as a cellular-dense tumor stroma, could negatively impact the prognosis of PDAC patients.

摘要

本研究评估了胰腺导管腺癌(PDAC)肿瘤组织中所有肿瘤坏死因子相关凋亡诱导配体(TRAIL)受体的表达情况。我们旨在将TRAIL受体表达作为一个纳入参数,用于未来一项针对PDAC患者采用基于TRAIL治疗方法的临床研究。考虑到PDAC促纤维增生性基质对PDAC治疗疗效的影响日益显现,本分析扩展至肿瘤基质细胞。此外,我们还对PDAC基质进行了特征描述。我们的回顾性队列研究(N = 50)纳入了经组织学确诊且接受手术的PDAC患者。通过免疫组织化学(IHC)评估肿瘤和基质细胞中TRAIL受体(DR4、DR5、DcR1、DcR2和骨保护素(OPG))的表达。通过抗波形蛋白IHC和马洛里三色染色评估肿瘤基质的数量。通过单变量Cox比例风险回归模型确定预后影响。在PDAC肿瘤和基质细胞中检测到功能性受体DR4和DR5的广泛表达以及诱饵受体的可变表达。在转移性肿瘤和基质细胞中也检测到了功能性受体。原发性PDAC肿瘤细胞中诱饵受体低表达或无表达与预后不良相关。在评估几乎80%的肿瘤块由基质组成后,我们发现原发性PDAC中细胞密集的基质与无复发生存期缩短相关。我们证明TRAIL功能性受体在PDAC中广泛表达,是基于TRAIL治疗的一个有前景的靶点。此外,我们证明肿瘤细胞中DcR1低表达和OPG缺失以及细胞密集的肿瘤基质可能对PDAC患者的预后产生负面影响。

相似文献

7
DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Cancer Biol Ther. 2014;15(12):1658-66. doi: 10.4161/15384047.2014.972183.
10
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer.
Sci Rep. 2019 Feb 11;9(1):1788. doi: 10.1038/s41598-018-37433-6.

引用本文的文献

1
Integrating AI/ML and multi-omics approaches to investigate the role of TNFRSF10A/TRAILR1 and its potential targets in pancreatic cancer.
Comput Biol Med. 2025 Jul;193:110432. doi: 10.1016/j.compbiomed.2025.110432. Epub 2025 May 26.
2
Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells.
Sci Adv. 2025 Jan 17;11(3):eadp9009. doi: 10.1126/sciadv.adp9009. Epub 2025 Jan 15.
3
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer.
MAbs. 2024 Jan-Dec;16(1):2438173. doi: 10.1080/19420862.2024.2438173. Epub 2024 Dec 9.
4
Focus on Pancreatic Cancer Microenvironment.
Curr Oncol. 2024 Jul 26;31(8):4241-4260. doi: 10.3390/curroncol31080316.
5
Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma.
Cell Rep Med. 2024 Aug 20;5(8):101685. doi: 10.1016/j.xcrm.2024.101685.
6
Antibody drug conjugates: hitting the mark in pancreatic cancer?
J Exp Clin Cancer Res. 2023 Oct 25;42(1):280. doi: 10.1186/s13046-023-02868-x.

本文引用的文献

1
TRAIL Induces Nuclear Translocation and Chromatin Localization of TRAIL Death Receptors.
Cancers (Basel). 2019 Aug 14;11(8):1167. doi: 10.3390/cancers11081167.
2
European cancer mortality predictions for the year 2019 with focus on breast cancer.
Ann Oncol. 2019 May 1;30(5):781-787. doi: 10.1093/annonc/mdz051.
3
MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma.
Theranostics. 2019 Jan 1;9(2):436-448. doi: 10.7150/thno.27576. eCollection 2019.
4
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer.
Sci Rep. 2019 Feb 11;9(1):1788. doi: 10.1038/s41598-018-37433-6.
5
Cancer statistics, 2019.
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
6
The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.
Am J Pathol. 2019 Jan;189(1):44-57. doi: 10.1016/j.ajpath.2018.09.009.
8
Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC.
BMC Cancer. 2018 Jul 31;18(1):777. doi: 10.1186/s12885-018-4688-8.
9
Tumor microenvironment participates in metastasis of pancreatic cancer.
Mol Cancer. 2018 Jul 30;17(1):108. doi: 10.1186/s12943-018-0858-1.
10
Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer.
Cancers (Basel). 2018 Jan 27;10(2):34. doi: 10.3390/cancers10020034.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验